Q-omics provides the consensus-scored FAM183DP profile across patient tissues and cancer cell-line models. FAM183DP expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, FAM183DP is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, FAM183DP RNA expression shows 7,640 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRC, and TGCT as cancer lineages where FAM183DP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM183DP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM183DP survival associations across molecular data types. FAM183DP RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM183DP RNA expression–survival associations across cancer types. High FAM183DP expression shows unfavorable associations in UCEC, TGCT and OV, but favorable associations in READ, SKCM and LUSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for FAM183DP RNA expression.
This table summarizes FAM183DP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM183DP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM183DP shows lower tumor expression in KIRC, KICH, LUSC, LIHC, LUAD and BRCA. The KIRC box plot shows higher FAM183DP RNA expression in normal versus tumor tissue (log2 FC = −0.691, t-test p < 0.001).
This table shows molecular features associated with FAM183DP in patient tissues and cancer cell lines. In patient samples, FAM183DP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
